Total Payments
$208,928
2024 Payments
$25,632
Companies
18
Transactions
174
Medicare Patients
36
Medicare Billing
$2,268
Payment Breakdown by Category
Research$192,047 (91.9%)
Travel$10,236 (4.9%)
Food & Beverage$6,354 (3.0%)
Education$290.43 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $192,047 | 56 | 91.9% |
| Travel and Lodging | $10,236 | 42 | 4.9% |
| Food and Beverage | $6,354 | 67 | 3.0% |
| Education | $290.43 | 9 | 0.1% |
Payments by Type
Research
$192,047
56 transactions
General
$16,881
118 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $86,036 | 12 | $0 (2022) |
| PFIZER INC. | $69,376 | 9 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $25,024 | 11 | $0 (2024) |
| Novo Nordisk AS | $10,474 | 42 | $0 (2019) |
| Eli Lilly and Company | $4,595 | 3 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $4,463 | 6 | $0 (2018) |
| SANOFI US SERVICES INC. | $2,105 | 16 | $0 (2018) |
| AstraZeneca UK Limited | $1,697 | 7 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $1,277 | 11 | $0 (2023) |
| Allergan Inc. | $985.14 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,632 | 27 | Teva Pharmaceuticals USA, Inc. ($25,012) |
| 2023 | $70,711 | 21 | PFIZER INC. ($68,463) |
| 2022 | $87,056 | 14 | Biohaven Pharmaceutical Holding Company Ltd. ($86,036) |
| 2021 | $2,566 | 11 | Eli Lilly and Company ($2,333) |
| 2020 | $3,131 | 17 | AstraZeneca UK Limited ($1,697) |
| 2019 | $4,576 | 23 | Novo Nordisk AS ($3,650) |
| 2018 | $5,972 | 28 | Novo Nordisk AS ($2,123) |
| 2017 | $9,283 | 33 | Novo Nordisk AS ($4,700) |
All Payment Transactions
174 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $475.15 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 12/12/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,541.00 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 11/27/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $8,529.30 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 10/30/2024 | Teva Pharmaceuticals USA, Inc. | — | — | In-kind items and services | $204.60 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 08/27/2024 | Teva Pharmaceuticals USA, Inc. | — | — | In-kind items and services | $68.20 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 08/23/2024 | Teva Pharmaceuticals USA, Inc. | — | — | In-kind items and services | $136.40 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 08/15/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $5,580.25 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 08/06/2024 | Teva Pharmaceuticals USA, Inc. | — | — | In-kind items and services | $68.20 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 05/02/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $8,000.00 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 04/24/2024 | Teva Pharmaceuticals USA, Inc. | — | — | In-kind items and services | $409.20 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $14.95 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $14.95 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention | Biohaven Pharmaceutical Holding Company Ltd. | $86,036 | 12 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $68,463 | 5 |
| A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | Teva Pharmaceuticals USA, Inc. | $25,012 | 10 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $4,595 | 3 |
| A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to I | SANOFI-AVENTIS U.S. LLC | $2,326 | 2 |
| EFC 12405 LixiLan-L | SANOFI-AVENTIS U.S. LLC | $1,530 | 1 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua?100/33 Versus Lantus? in Ethnically/Racially Di | SANOFI US SERVICES INC. | $1,240 | 9 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular | SANOFI US SERVICES INC. | $865.25 | 7 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $616.00 | 2 |
| iGlarLixi HEDIS; Efficacy of Insulin Glargine/Lixisenatide Fixed-Ratio Combination in Patients with T2D According to Healthcare Effectiveness Data and Information Set (HEDIS) Measures | SANOFI-AVENTIS U.S. LLC | $568.66 | 1 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $438.98 | 3 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 22 | 52 | $6,058 | $2,214 |
| 2020 | 1 | 14 | 18 | $882.00 | $53.94 |
Total Patients
36
Total Services
70
Medicare Billing
$2,268
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 30 | $4,980 | $2,029 | 40.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 11 | 22 | $1,078 | $184.80 | 17.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 14 | 18 | $882.00 | $53.94 | 6.1% |
About Dr. Danny Sugimoto, MD
Dr. Danny Sugimoto, MD is a Internal Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679661821.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Danny Sugimoto, MD has received a total of $208,928 in payments from pharmaceutical and medical device companies, with $25,632 received in 2024. These payments were reported across 174 transactions from 18 companies. The most common payment nature is "" ($192,047).
As a Medicare-enrolled provider, Sugimoto has provided services to 36 Medicare beneficiaries, totaling 70 services with total Medicare billing of $2,268. Data is available for 2 years (2020–2023), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Chicago, IL
- Active Since 10/11/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1679661821
Products in Payments
- ZAVZPRET (Drug) $68,463
- SOLIQUA (Drug) $5,665
- Tresiba (Drug) $3,250
- Saxenda (Drug) $2,119
- Ozempic (Drug) $989.87
- LEQVIO (Drug) $971.92
- SAR439977 (Drug) $865.25
- TRADJENTA (Drug) $438.98
- EMGALITY (Drug) $140.67
- VYEPTI (Biological) $79.93
- Victoza (Drug) $72.81
- Repatha (Biological) $49.68
- TOUJEO (Drug) $37.63
- Wegovy (Drug) $32.27
- BOTOX COSMETIC (Biological) $13.14
- AJOVY (Biological) $11.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chicago
Dr. Myles Wolf, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Merle Diamond, Md, MD
Internal Medicine — Payments: $1.4M
Internal Medicine $1.4M
Dr. Elizabeth Kiracofe, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Robert Kushner, Md, MD
Internal Medicine — Payments: $549,886
Internal Medicine $549,886
Dr. Adam Stein, M.d, M.D
Internal Medicine — Payments: $503,325
Internal Medicine $503,325
Devalingam Mahalingam, M.d, M.D
Internal Medicine — Payments: $501,247
Internal Medicine $501,247